Trial Profile
Safety of Ticagrelor plus Warfarin versus Traditional Triple Antithrombotic Therpay Regimen in Patients with Persistent or Permanent Atrial Fibrillation and undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel; Warfarin
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Adverse reactions
- 12 Apr 2023 Status changed from recruiting to completed.
- 15 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
- 15 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Feb 2018.